by admin | 8th September 2023 | News
Full enrollment achieved on September 6th with a total of 240 patients enrolled in study Top-line data planned for release in December 2023 Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endpoints covering both a sign... by admin | 30th August 2023 | News
Full enrollment anticipated by first week of September OKYO on schedule to release top-line data before end of 2023 Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED London... by admin | 28th July 2023 | News
London and New York, NY – July 28, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this... by admin | 6th June 2023 | News
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain component Top-line data from trial anticipated in Q4, 2023 London and New York, NY, June 6, 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an... by admin | 19th May 2023 | News
LONDON and NEW YORK, May 19, 2023 — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) hereby announces that following the implementation of the share capital consolidation and collapse of its ADS program, it is expected that new OKYO ordinary shares will be listed...